TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36461034

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Waist-to-Height Ratio (WHtR)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: A Body Shape Index (ABSI)
Number of subjects: 15773
Study: 36461061

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 26709

Group type: COMPARATOR
Intervention: Non-exclusive breastfeeding
Number of subjects: 26709

Group type: EXPERIMENTAL
Intervention: Overall exclusive breastfeeding rates over time
Number of subjects: 26709

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding following WHO guidelines publication
Number of subjects: 26709
Study: 36461087

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) program
Number of subjects: 40
Study: 36461134

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (20-50 min, 3 times/week for 6 months)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low-intensity stretching (20-50 min, 3 times/week for 6 months)
Number of subjects: 96
Study: 36461157

Group type: EXPERIMENTAL
Intervention: Sedation for research procedures in CLN3 (28 anesthetic events)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sedation for research procedures in GM1 (19 anesthetic events)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Overall sedation outcomes for both conditions (47 anesthetic events)
Number of subjects: 47
Study: 36461750

Group type: EXPERIMENTAL
Intervention: HF nurse intervention (n=53)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Audit and feedback combined with natriuretic peptide testing
Number of subjects: 593

Group type: COMPARATOR
Intervention: Renin-angiotensin-aldosterone system inhibitors or beta-blockers
Number of subjects: 593
Study: 36461912

Group type: EXPERIMENTAL
Intervention: Rice Bran (RB) supplementation (15 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 36461942

Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine
Number of subjects: 0
Study: 36462064

Group type: EXPERIMENTAL
Intervention: HD Grid high-density mapping catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: 20-pole circumferential mapping catheter (CMC-20)
Number of subjects: 20
Study: 36463082

Group type: EXPERIMENTAL
Intervention: Successful eradication of H. pylori
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Correa's steps III-V
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Age, OLGA stages ≥ I, OLGIM stages ≥ I
Number of subjects: 1824
Study: 36463104

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg and gemcitabine 1,250 mg/m²
Number of subjects: 36
Study: 36463140

Group type: EXPERIMENTAL
Intervention: Ongoing observational cohort study
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Follow-up data collection
Number of subjects: 10000
Study: 36463160

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (poor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (lower-middle class)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower educational attainment (high school)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower educational attainment (< high school)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age 25-34 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age 35-50 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Employment in food services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Employment in healthcare and within home, and primiparity
Number of subjects: 0
Study: 36463173

Group type: EXPERIMENTAL
Intervention: Peer Recovery Support (PRS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Family Treatment Drug Court (FTDC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Medications for Opioid Use Disorder (MOUD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nurturing Parent Program (NPP)
Number of subjects: 17
Study: 36463180

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS) once daily (OD) for 1 year
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo OD for 1 year
Number of subjects: 58
Study: 36463214

Group type: EXPERIMENTAL
Intervention: Telemedicine-based program (PARTNER UP) providing access to oral pre-exposure prophylaxis (PrEP) and medication for opioid use disorder (MOUD) through syringe services programs (SSPs). Initial in-person visit followed by weekly telemedicine visits in month 1 and monthly visits until month 6.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Telemedicine visits (PARTNER UP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Initial in-person meeting
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Visit schedule of PARTNER UP
Number of subjects: 17
Study: 36463219

Group type: EXPERIMENTAL
Intervention: ARAT-VR
Number of subjects: 30
Study: 36463457

Group type: EXPERIMENTAL
Intervention: PIVOT HD (PTC518)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIGNAL (pepinemab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SELECT HD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: uniQure AMT-130
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VIBRANT HD
Number of subjects: 0
Study: 36463540

Group type: EXPERIMENTAL
Intervention: O3® Regional Oximetry on quadriceps
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: O3® Regional Oximetry on flank
Number of subjects: 26
Study: 36463542

Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Head-down tilt position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Changes in cardiac index and stroke volume index
Number of subjects: 20
Study: 36463561

Group type: EXPERIMENTAL
Intervention: Ixazomib-based triple-drug therapy
Number of subjects: 320
Study: 36464141

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg QD
Number of subjects: 988

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study: 36464218

Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 116

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 116
Study: 36464242

Group type: EXPERIMENTAL
Intervention: Monofilament suture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multifilament suture
Number of subjects: 0
Study: 36464584

Group type: EXPERIMENTAL
Intervention: Microbiome interactions with cancer immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical efforts to utilize microbiome knowledge
Number of subjects: 0
Study: 36464714

Group type: EXPERIMENTAL
Intervention: Semi-automated vitrification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual vitrification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 0
Study: 36464928

Group type: EXPERIMENTAL
Intervention: PTSD symptoms measured using the PTSD Checklist for DSM-5 (PCL-5)
Number of subjects: 254
Study: 36465342

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Grade 4 lymphopenia during CCRT (3 weeks)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: G1-4 lymphopenia 2 months after CCRT
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: G1-4 lymphopenia 6 months after CCRT (6m-post-CCRT)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: TLC nadir
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 6m-post-CCRT G1-4 lymphopenia
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Radiation dose
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: GTV volume
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Baseline TLC
Number of subjects: 381
Study: 36465445

Group type: EXPERIMENTAL
Intervention: Elevated serum level of calpains
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum level of calpains
Number of subjects: 70
Study: 36465469

Group type: EXPERIMENTAL
Intervention: Endovascular intervention for tibial runoff
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Non-intervention for tibial runoff
Number of subjects: 1200
Study: 36465905

Group type: EXPERIMENTAL
Intervention: Combination of Radium-223
Number of subjects: 0
Study: 36465920

Group type: EXPERIMENTAL
Intervention: Closed-loop oxygen control for 2 hours
Number of subjects: 23

Group type: COMPARATOR
Intervention: Manual oxygen titrations for 2 hours
Number of subjects: 23
Study: 36466215

Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy (EAET) class
Number of subjects: 74
Study: 36466423

Group type: EXPERIMENTAL
Intervention: Long-term fasting (LF) for 9 ± 3 days (250 kcal/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-term fasting (LF) for 12 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up after fasting
Number of subjects: 100
Study: 36466746

Group type: COMPARATOR
Intervention: VMATc (2 coplanar arcs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: VMATc + nc (coplanar and 3 non-coplanar arcs)
Number of subjects: 10
Study: 36467036

Group type: EXPERIMENTAL
Intervention: Buprenorphine plasma concentrations sustained at 2-3 ng/ml
Number of subjects: 543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study: 36467262

Group type: EXPERIMENTAL
Intervention: Active bilateral vagal stimulation (45 min duration with 30s alternative episodes of active/rest periods; 3mA; 200-300μs current width, 25Hz)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study: 36467287

Group type: EXPERIMENTAL
Intervention: Clinical care bundle for early detection and first-response PPH management
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: In-service training on emergency obstetric care
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Objective measurement of blood loss
Number of subjects: 45
Study: 36467452

Group type: EXPERIMENTAL
Intervention: Bosutinib 100 mg QD to 400 mg QD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bosutinib treatment
Number of subjects: 20
Study: 36467815

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor de-escalation or discontinuation
Number of subjects: 0
Study: 36468466

Group type: EXPERIMENTAL
Intervention: SIII-GC-PD
Number of subjects: 72
Study: 36468499

Group type: EXPERIMENTAL
Intervention: Automated SMS (n = 132)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Automated and tailored SMS + Peer Navigation (SMS + PN) (n = 133)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: SMS + PN
Number of subjects: 752

Group type: COMPARATOR
Intervention: Standard of Care (SOC) (n = 87)
Number of subjects: 752
Study: 36468635

Group type: EXPERIMENTAL
Intervention: BMAC intra-articular injection combined with subchondral BMAC injection
Number of subjects: 86

Group type: COMPARATOR
Intervention: BMAC intra-articular injection alone
Number of subjects: 86
Study: 36469077

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study: 36469095

Group type: EXPERIMENTAL
Intervention: Post-transplant CD45RA-depleted donor lymphocyte infusions (DLI)
Number of subjects: 19
Study: 36469103

Group type: EXPERIMENTAL
Intervention: Digital measures from smartphone-based tests (Floodlight Proof-of-Concept app) including Draw a Shape Test and Pinching Test.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Standard clinical measures (e.g., Nine-Hole Peg Test [9HPT]).
Number of subjects: 62
Study: 36469250

Group type: EXPERIMENTAL
Intervention: Kollidon VA64®-based eliapixant formulation (400 mg; fasted)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate-release eliapixant
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two amorphous solid dispersion (ASD) formulations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suspension-based formulation
Number of subjects: 30
Study: 36469289

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (Nutritious Eating with Soul study)
Number of subjects: 150
Study: 36469321

Group type: EXPERIMENTAL
Intervention: Pacritinib (400 mg on day 1 followed by 200 mg twice daily on days 2-14)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 200
Study: 36469400

Group type: EXPERIMENTAL
Intervention: Enhanced PrEP implementation strategy in STI clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assisted partner notification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinic staff participants
Number of subjects: 0
Study: 36469726

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy initiated at age 2 to <4 years
Number of subjects: 3318

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy initiated at age 4 to <6 years
Number of subjects: 3318

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy initiated at age ≥6 years
Number of subjects: 3318
Study: 36469736

Group type: EXPERIMENTAL
Intervention: Adipose tissue insulin sensitivity/resistance evaluated using OGTT-derived surrogates
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Whole-body insulin sensitivity
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Low postprandial free fatty acid concentrations
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Change in body mass index (BMI) z score
Number of subjects: 213
Study: 36469840

Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy in patients with epithelial ovarian cancer
Number of subjects: 30
Study: 36469915

Group type: EXPERIMENTAL
Intervention: Team-based care with a clinical decision support system (CDSS)
Number of subjects: 11132

Group type: COMPARATOR
Intervention: Team-based care alone
Number of subjects: 11132
Study: 36469995

Group type: EXPERIMENTAL
Intervention: Multi-sample capture-recapture analysis using four statewide datasets (Registry of Vital Statistics, EMS, PDMP, Kentucky Medicaid)
Number of subjects: 1000
Study: 36470149

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Inhaled corticosteroid-containing therapy
Number of subjects: 10355
Study: 36470291

Group type: EXPERIMENTAL
Intervention: Trifluridine-tipiracil plus bevacizumab
Number of subjects: 856

Group type: COMPARATOR
Intervention: Capecitabine plus bevacizumab
Number of subjects: 856
Study: 36470418

Group type: EXPERIMENTAL
Intervention: PPAH risk model
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Targeted drugs
Number of subjects: 247
Study: 36470464

Group type: EXPERIMENTAL
Intervention: Tympanostomy tube placement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 100
Study: 36470507

Group type: EXPERIMENTAL
Intervention: Indeterminate diastolic function
Number of subjects: 330

Group type: COMPARATOR
Intervention: No diastolic dysfunction
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Definite diastolic dysfunction
Number of subjects: 330
Study: 36470546

Group type: EXPERIMENTAL
Intervention: SGLT2-I users
Number of subjects: 646

Group type: COMPARATOR
Intervention: non-SGLT2-I users
Number of subjects: 646
Study: 36470745

Group type: EXPERIMENTAL
Intervention: Non-opioid analgesics (NSAID, paracetamol, metamizole)
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 898

Group type: COMPARATOR
Intervention: Non-opioid analgesics
Number of subjects: 898

Group type: COMPARATOR
Intervention: Non-opioid analgesics before end of surgery
Number of subjects: 898

Group type: COMPARATOR
Intervention: Opioid doses
Number of subjects: 898
Study: 36470974

Group type: EXPERIMENTAL
Intervention: PAC-1 at 750 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PAC-1
Number of subjects: 48
Study: 36471036

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36471059

Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE) as an alternative to CT colonography
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE) as an alternative to AA colonoscopy
Number of subjects: 65
Study: 36471142

Group type: EXPERIMENTAL
Intervention: Protamine administration at a rate of 25 mg·min
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Protamine:heparin ratio of 0.3
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Protamine:heparin ratio of 0.5
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Post-CPB activated clotting time
Number of subjects: 28
Study: 36471184

Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry analysis at T0 and T1
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels on postoperative day 1 (T1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Prevalence of hypocoagulation
Number of subjects: 68
Study: 36471222

Group type: EXPERIMENTAL
Intervention: Single 300-mg oral dose of tucatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study: 36471253

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% (Qutenza®) patch applied at three time intervals
Number of subjects: 130
Study: 36471392

Group type: EXPERIMENTAL
Intervention: Transition of care model
Number of subjects: 0
Study: 36471891

Group type: EXPERIMENTAL
Intervention: Trauma-informed yoga intervention (6-week, twice-weekly sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36472134

Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lemborexant 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: zolpidem tartrate extended-release 6.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 36472162

Group type: COMPARATOR
Intervention: Medium-dose triple therapy
Number of subjects: 17161

Group type: COMPARATOR
Intervention: High-dose triple therapy
Number of subjects: 17161

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 17161

Group type: COMPARATOR
Intervention: High-dose ICS/LABA
Number of subjects: 17161
Study: 36472189

Group type: EXPERIMENTAL
Intervention: Heart Failure (HF)
Number of subjects: 2981

Group type: COMPARATOR
Intervention: Community without HF
Number of subjects: 2981
Study: 36472300

Group type: EXPERIMENTAL
Intervention: High-specific-activity I-131 meta-iodobenzylguanidine (dose: ~18.5 GBq (~500 mCi))
Number of subjects: 68
Study: 36472416

Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 21149

Group type: COMPARATOR
Intervention: Self-management interventions
Number of subjects: 21149

Group type: COMPARATOR
Intervention: Educational with self-management interventions
Number of subjects: 21149
Study: 36472536

Group type: EXPERIMENTAL
Intervention: Deep learning model using diffusion-weighted imaging (DWI) and clinical information to predict hypoperfusion lesion and identify target mismatch profile.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perfusion MRI as the reference standard for comparison.
Number of subjects: 0
Study: 36472579

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: exercise treatment
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: liraglutide treatment
Number of subjects: 195
Study: 36472719

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) treatment including direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Control group (non-anaemic patients)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: OAC therapy in anaemic patients
Number of subjects: 958
Study: 36472728

Group type: EXPERIMENTAL
Intervention: Relugolix (loading dose 360 mg at Day -14, then 120 mg/day until Day -1; followed by 120 mg/day with apalutamide 240 mg from Day 1 to Day 28)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Relugolix + Apalutamide (120 mg/day of relugolix with 240 mg of apalutamide from Day 1 to Day 28)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relugolix monotherapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relugolix + Apalutamide
Number of subjects: 12
Study: 36472802

Group type: EXPERIMENTAL
Intervention: Intra-fraction Motion Review (IMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kilovoltage Intra-fraction Motion management (KIM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MV/kV triangulation
Number of subjects: 0
Study: 36472876

Group type: EXPERIMENTAL
Intervention: Elaboration on common errors in patient treatment combined with individualized mailed feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36472884

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 3398
Study: 36472904

Group type: EXPERIMENTAL
Intervention: Call for Life Uganda (CFLU) interactive voice response tool providing daily pill reminders, preappointment reminders, symptom reporting, and health promotion tips.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Call for Life Uganda (CFLU) interactive voice response tool.
Number of subjects: 0
Study: 36472992

Group type: EXPERIMENTAL
Intervention: Malnutrition identified using GLIM criteria
Number of subjects: 381000

Group type: EXPERIMENTAL
Intervention: Frailty assessed using the accumulation of deficits model
Number of subjects: 381000

Group type: EXPERIMENTAL
Intervention: Frailty assessed using the phenotype model
Number of subjects: 381000

Group type: EXPERIMENTAL
Intervention: Sarcopenia assessed according to EWGSOP standards
Number of subjects: 381000
Study: 36473106

Group type: EXPERIMENTAL
Intervention: Baricitinib + methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab + methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36473121

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg loading dose followed by 0.5 mg/day until discharge) plus atorvastatin 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colchicine plus atorvastatin
Number of subjects: 0